Clinical Trials Logo

Sensorineural Hearing Loss clinical trials

View clinical trials related to Sensorineural Hearing Loss.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04934605 Active, not recruiting - Clinical trials for Sensorineural Hearing Loss

Genotype-phenotype Correlation of SLC26A4 in CI Patients With EVA

Start date: May 1, 2010
Phase:
Study type: Observational

To explore the genotype-phenotype correlation of SLC26A4 mutations in cochlear-implanted patients with enlarged vestibular aqueduct.

NCT ID: NCT04750642 Active, not recruiting - Clinical trials for Sensorineural Hearing Loss

Cochlear Implant With Dexamethasone Eluting Electrode Array

Start date: October 4, 2021
Phase: N/A
Study type: Interventional

An evaluation of Cochlear's cochlear implant electrode array which passively elutes dexamethasone for a defined period of time to help reduce inflammatory responses.

NCT ID: NCT03107871 Active, not recruiting - Clinical trials for Sensorineural Hearing Loss

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

ValEAR
Start date: August 31, 2018
Phase: Phase 2
Study type: Interventional

The overall goal of this study is to determine the clinical benefit and safety of antiviral therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants. We will conduct a multi-center double-blind randomized placebo-controlled trial to determine whether hearing-impaired infants with asymptomatic cCMV have better hearing and language outcomes if they receive valganciclovir antiviral treatment. We will also determine the safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired infants. This study will be unique in that the cohort enrolled will only include hearing-impaired infants with asymptomatic cCMV. Primary Objective: To determine if treatment of cCMV-infected hearing impaired infants with isolated hearing loss with the antiviral drug valganciclovir reduces the mean slope of total hearing thresholds over the 20 months after randomization compared to untreated cCMV-infected infants with isolated hearing loss. Main Secondary Objectives: 1. To determine if valganciclovir treatment improves the following outcomes when compared to the control group: 1. The slope of best ear hearing thresholds over the 20 months after randomization. 2. The MacArthur-Bates Communicative Development Inventory (CDI) percentile score for words produced at 20 months of age. 2. To evaluate safety measures based on all grade 3 or greater new adverse events designated by the NIAID Division of AIDS (DAIDS) toxicity tables.